SERENEX LANDS MAJOR EXPANSION OF GSK PARTNERSHIP

Serenex has signed a master drug discovery agreement with GlaxoSmithKline (GSK), expanding a partnership originally forged a couple years ago. As part of the deal, GSK researchers from all over the company will be able to send potential drug candidates to Serenex, which will use its proteome mining drug discovery technology to gather data on the compounds. GSK will use that information to help develop new drugs for its pipeline.
Triangle Business Journal